PMID- 32833506
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1947-5543 (Electronic)
IS  - 1947-5543 (Linking)
VI  - 18
IP  - 6
DP  - 2020 Dec
TI  - Data Sharing Solutions for Biobanks for the COVID-19 Pandemic.
PG  - 581-586
LID - 10.1089/bio.2020.0040 [doi]
AB  - The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully 
      understood. Whether an individual has traveled outside their respective country 
      or never left their community, COVID-19 is a highly contagious illness, which can 
      result in high death rates. Biobanks will play a role in providing tools to 
      examine data from those receiving treatment along with reviewing the current and 
      long treatment outcomes associated with this novel coronavirus disease. A 
      diverse, global network made up of laboratory scientists, clinical researchers, 
      epidemiologists, data science teams, physicians, and so on must have a 
      standardized, collaborative, virtual biobanking solution to share clinical 
      expertise and evidence-based solutions. This virtual biobank must be centrally 
      managed to ensure standardized quality assurance and quality control efforts. 
      Virtual biobanks will eliminate the need to transport samples between two 
      locations for a specific study, minimizing the risk of contamination. It is 
      necessary for virtual biobanks to upload imaging data from those patients 
      diagnosed with COVID-19. Standardized, collected information will be essential in 
      the area of discovery and validation of disease markers as well as novel 
      therapeutic strategies. It is essential for biobanks to collect COVID-19 
      specimens along with corresponding clinical and demographic data from COVID-19 
      diagnostic testing. Because COVID-19 is an acute respiratory illness, proper 
      collection procedures must be in place to collect respiratory samples for 
      biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory 
      Information Management System (LIMS) is an efficient tool to seamlessly manage a 
      data sharing network. Data entered into LIMS will be beneficial in designing much 
      needed clinical trials to address any unmet needs to better address clinical 
      treatment and outcomes. The partners or entities associated with the COVID-19 
      data sharing network will be able to effectively communicate, view data, and 
      images associated with their respective research interest to advance COVID-19 
      research and data driven, clinical care.
FAU - Paul, Shonali
AU  - Paul S
AD  - CloudLIMS.com, Wilmington, Delaware, USA.
FAU - Chatterjee, Mrinal Kanti
AU  - Chatterjee MK
AD  - CloudLIMS.com, Wilmington, Delaware, USA.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - Biopreserv Biobank
JT  - Biopreservation and biobanking
JID - 101507284
SB  - IM
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - *COVID-19/diagnosis/epidemiology
MH  - *COVID-19 Testing
MH  - Humans
MH  - *Information Dissemination
MH  - *Pandemics
MH  - *SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19 LIMS
OT  - COVID-19 biobanks
OT  - COVID-19 diagnostic testing
OT  - COVID-19 specimens
OT  - COVID-19 testing
EDAT- 2020/08/25 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1089/bio.2020.0040 [doi]
PST - ppublish
SO  - Biopreserv Biobank. 2020 Dec;18(6):581-586. doi: 10.1089/bio.2020.0040. Epub 2020 
      Aug 19.